Chronic Heart FailureNCT07795359
A Study Evaluating an Implantable Cardiac Microcurrent Device in Patients With Chronic Heart Failure
A study testing Subcutaneous cardiac microcurrent treatment in people with Chronic Heart Failure and Left Ventricular (LV) Systolic Dysfunction, run by Berlin Heals GmbH.
Trial summary
This study evaluates the safety and performance/effectiveness of the C-MIC System, an active implantable medical device designed to treat patients with heart failure with reduced ejection fraction (HFrEF). Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Chronic Heart Failure, Left Ventricular (LV) Systolic Dysfunction, Ischemic and Non-ischemic Cardiomyopathy
- What is being tested?
- Subcutaneous cardiac microcurrent treatment
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- Sep 2026to Oct 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Only for Stratum 1: Patients with HFrEF with non-ischemic disease etiology1
- Only for Stratum 2: Patients with HFrEF with ischemic disease etiology. All Participants
- Informed consent in writing obtained from patient.
- Ambulatory patients with symptomatic chronic heart failure in NYHA functional class II-IV at the time of screening lasting for more than 1 year based on the date of diagnosis. Participants in NYHA II at screening must have one documented episode of NYHA III during the prior 6 months with either hospitalization or increase of heart failure medication dosage.
- Documented worsening heart failure episode within 12 months prior to screening, defined as HF hospitalization, requirement for intravenous diuretic therapy, or escalation of oral diuretic therapy due to clinically significant worsening HF symptoms requiring medical intervention, as evidenced by source documentation.
- Patients who have a baseline LVEF of ≥ 20 % and ≤ 40 % in echocardiography as assessed by the core-lab within 30 days prior to device implantation.
Show all 10Show fewer
- Female and male patients aged 18 years to ≤ 80 years.
- Patients receiving appropriate, stable guideline-directed medical therapy for heart failure for at least 90 days prior to screening. [Note: Stable therapy is defined as no more than a 50 % increase or 50 % decrease in dose. If a patient is unable to take guideline recommended doses of heart failure medication, documented evidence must be available.]
- Patients who are able to perform a 6-minute walk test. At screening, the 6-minute walk test distance is between 100 and 450 m.
- Body habitus that, in the opinion of the Investigator, permits safe and feasible implantation of the C-MIC System, including adequate anatomical access and visualization required for the procedure
Who cannot join
- Patients who are not likely to experience improvement of their chronic heart failure by the microcurrent therapy, because the causes of the disease cannot be influenced even if the patients fulfill the indication for use of the device or if the therapy with the C MIC System is not possible or might be associated with unknown risks:
- Patients who have a potentially correctible cause of heart failure, such as severe valvular heart disease or congenital heart disease.
- Patients with an indication for a CRT system according to current guidelines.
- Patients who have been hospitalized for heart failure which required the use of inotropic support within 90 days before screening.
- Patients with systolic blood pressure (SBP) above 150 mmHg and diastolic blood pressure (DBP) above 90 mmHg despite optimal antihypertensive medical treatment.
- Patients with SBP < 90 mmHg at screening while not receiving vasopressor therapy, as assessed by the Investigator.
Show all 29Show fewer
- Patients with hemoglobin blood level < 11 g/dL.
- Patients with primary severe pulmonary hypertension defined as estimated systolic pulmonary artery pressure (SPAP) > 80 mmHg on screening echocardiography.
- Patients who have genetic connective tissue disease (for example Marfan syndrome).
- Patients with a prosthetic tricuspid valve.
- Patients in whom access for implantation of the leads cannot be obtained (i.e. known venous occlusion, post radiation therapy).
- Patients with other anatomical features (e.g., thoracic deformities) that, in the investigator's judgment, would make straightforward device placement unlikely.
- Patients with a pacemaker, an ICD system, a CRT system or with a CCM system* [* In case the patient requires a pacemaker or has a CCM device, the impulses given from the device could change the C-MIC System setting into a safe state and stop the microcurrent.]
- Current pregnancy or Breast feeding/lactating women
- Women of childbearing potential (WOCBP), defined as all women who are physiologically capable of becoming pregnant, unless they are using a highly effective methods of contraception (failure rate < 1 % per year), as determined by the investigator, for at least 2 months prior to C-MIC therapy and continuing until 1 month after completion of therapy
- Patients whose exercise tolerance is limited by a condition other than heart failure (e.g. chronic obstructive pulmonary disease, peripheral vascular disease, orthopedic or rheumatologic conditions) or who are unable to participate in a 6 minute walk test.
- Patients on immunosuppressive therapy.
- Patients with present malignancy.
- Patients with an active infection considered by the investigator to be unsafe for the patient's participation in the trial.
- Patients with renal dysfunction, i.e., estimated glomerular filtration rate (eGFR) <25 mL/min/1.73 m².
- Patients with history or presence of relevant liver diseases or hepatic dysfunction as indicated by abnormal liver function tests at screening and baseline: ALT (SGPT), AST (SGOT), GGT, alkaline phosphatase (ALP) and serum bilirubin > 2 × upper limit of normal (ULN). Increase of these liver enzymes caused by cardiac disorders in the absence of other possible causes of liver damage are not meant by this.
- Patients with a history of drug or alcohol abuse within the 12 months prior to screening.
- Patients who, in the opinion of the Principal Investigator, are unlikely to comply with the protocol requirements, instructions and trial related restrictions, e.g., uncooperative attitude, inability to return for follow-up visits, psychological illness, and improbability of completing the trial.
- Participation in any study of an investigational device or drug within 90 days prior to planned study.
- Vulnerable Patients (e.g. patients requiring a legal representative, patients kept in detention, any service within the army, and employees of the sponsor or at an investigator site).
- Patients who are not able to avoid the following areas (i.e. due to work): a) Areas with strong magnetic fields. b) Areas with strong external electrical influences. c) Areas with a warning notice "Access prohibited for pacemaker patients" or similar. d) Areas with high temperatures Stratum 2 only (ischemic etiology)
- Acute coronary event within 3 months prior to screening (def.: unstable angina or STEMI or NSTEMI).
- Evidence of significant myocardial scar or left ventricular aneurysm based on imaging (e.g., echocardiography or other modalities), as assessed by the investigator.
- Relevant coronary stenosis with indication for re-vascularization (def.: ≥ 50 % stenosis in LMCA, ≥ 70 % stenosis in LAD, RCA, CX.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Double Blind, Randomized, Sham Controlled Parallel-group Study, Evaluating the Performance of the Berlin Heals Cardiac Microcurrent (C-MIC) System With a Subcutaneously Implanted Left Ventricular Lead in Patients With Chronic Heart Failure With Reduced Ejection Fraction Stratified by Disease Etiology
This study evaluates the safety and performance/effectiveness of the C-MIC System, an active implantable medical device designed to treat patients with heart failure with reduced ejection fraction (HFrEF). The system delivers a non-excitatory, constant direct electrical microcurrent (DC) to the heart with the aim of improving cardiac function.
The C-MIC System is intended for use in patients with ischemic or non-ischemic dilated cardiomyopathy who have symptomatic, ambulatory heart failure despite receiving guideline-directed medical therapy. Eligible patients must have a left ventricular ejection fraction (LVEF) between ≥20% and ≤40%.
The device is implanted in the catheterization laboratory using a minimally invasive procedure that does not require open-heart surgery. Following implantation, patients receive C-MIC Therapy for a duration of six months. The therapy is designed to improve left ventricular performance, as well as functional capacity and patient well-being, including 6-minute walk distance, quality of life, and New York Heart Association (NYHA) functional class.
- Conditions
- Chronic Heart Failure, Left Ventricular (LV) Systolic Dysfunction, Ischemic and Non-ischemic Cardiomyopathy
- Being tested
- Subcutaneous cardiac microcurrent treatment
- Medical subject headings
- Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Subcutaneous cardiac microcurrent treatmentDevice
The C-MIC System is implanted subcutaneously using a minimally invasive, non-open-heart procedure performed in a catheterization laboratory. Following randomization, C-MIC Therapy is either inactive or active from Day 1 through Day 180 and active or inactive, respectively, from Day 180 through Day 360.
| Study group | Role | What they receive |
|---|---|---|
| Stratum 1: Ischemic Etiology | Other | Stratum 1a: Active → Inactive Stratum 1b: Inactive → Active Receives: Device: Subcutaneous cardiac microcurrent treatment |
| Stratum 2: Non-Ischemic Etiology | Other | Stratum 2a: Active → Inactive Stratum 2b: Inactive → Active Receives: Device: Subcutaneous cardiac microcurrent treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at Month 6
The Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) assesses heart failure symptoms and physical limitations. Scores range from 0 to 100, with higher scores indicating better health status. Change from baseline is calculated as the Month 6 score minus the baseline score; a positive change indicates improvement.
Measured: From baseline to 6 months
Change From Baseline in 6-Minute Walk Distance at Month 6
The 6-Minute Walk Test measures functional exercise capacity as the distance, in meters, that a participant can walk in 6 minutes. Change from baseline is calculated as the Month 6 distance minus the baseline distance; a positive change indicates improvement.
Measured: From baseline to 6 months
Ordinal Shift From Baseline in New York Heart Association Functional Class at Month 6
New York Heart Association (NYHA) Functional Class is a clinician-assessed, 4-category ordinal classification of heart failure severity: Class I indicates no limitation of physical activity, Class II indicates slight limitation, Class III indicates marked limitation, and Class IV indicates symptoms at rest. A shift to a lower class indicates improvement, and a shift to a higher class indicates worsening.
Measured: From baseline to 6 months
Patient Global Assessment of Change Score at Month 6
The Patient Global Assessment of Change is a participant-reported assessment of overall change in health status relative to baseline. It is measured on a 7-point ordinal scale ranging from 1 ("markedly worse") to 7 ("markedly improved"), with 4 indicating "no change." Higher scores indicate a more favorable assessment.
Measured: 6 months
Percentage of Participants Who Are Echocardiographic Responders at Month 6
An echocardiographic responder is a participant who meets at least 1 of the following criteria at Month 6 compared with baseline:
- Increase in left ventricular ejection fraction (LVEF) of at least 5 percentage points
- Improvement in global longitudinal strain (GLS) of at least 2 percentage points, defined as an increase in the absolute magnitude of GLS
- Relative reduction in left ventricular end-diastolic volume index (LVEDVi) of at least 10%
- Relative reduction in left ventricular end-systolic volume index (LVESVi) of at least 10% Each participant will be counted once as a responder if at least 1 criterion is met. The outcome will be reported as the percentage of participants classified as echocardiographic responders.
Measured: From baseline to 6 months
Change From Baseline in N-Terminal Pro-B-Type Natriuretic Peptide Concentration at Month 6
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a blood biomarker of heart failure severity and is measured in picograms per milliliter (pg/mL). Change from baseline is calculated as the Month 6 concentration minus the baseline concentration; a negative change indicates a reduction in NT-proBNP.
Measured: From baseline to 6 months
Secondary outcomes (1)
Change in Left Ventricular Ejection Fraction From Month 6 to Month 12
Left ventricular ejection fraction (LVEF) is measured by echocardiography and reported as a percentage. Change is calculated as the Month 12 LVEF minus the Month 6 LVEF. A positive value indicates an increase in LVEF, whereas a negative value indicates a decline. This outcome will assess maintenance of the LVEF improvement observed at the end of the initial 6-month treatment period.
Measured: From 6 monts to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2026
- Study startSep 2026 (estimated)
- Primary completionSep 2027 (estimated)
- Study completionOct 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Berlin Heals GmbH
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07795359
- Sponsor's protocol ID
- C-MIC-IV
- Status last verified
- Aug 2026
- First submitted
- 10 Aug 2026
- Last updated
- 31 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Double Blind, Randomized, Sham Controlled Parallel-group Study, Evaluating the Performance of the Berlin Heals Cardiac Microcurrent (C-MIC) System With a Subcutaneously Implanted Left Ventricular Lead in Patients With Chronic Heart Failure With Reduced Ejection Fraction Stratified by Disease Etiology
- ClinicalTrials.gov ID
- NCT07795359
- Acronym / sponsor ID
- C-MIC-IV
- Conditions
- Chronic Heart Failure, Left Ventricular (LV) Systolic Dysfunction, Ischemic and Non-ischemic Cardiomyopathy
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Berlin Heals GmbHIndustry (pharma, biotech, devices)
- Study start
- Sep 2026 (estimated)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Oct 2028 (estimated)
- First posted
- 31 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the safety and performance/effectiveness of the C-MIC System, an active implantable medical device designed to treat patients with heart failure with reduced ejection fraction (HFrEF). The system delivers a non-excitatory, constant direct electrical microcurrent (DC) to the heart with the aim of improving cardiac function.
The C-MIC System is intended for use in patients with ischemic or non-ischemic dilated cardiomyopathy who have symptomatic, ambulatory heart failure despite receiving guideline-directed medical therapy. Eligible patients must have a left ventricular ejection fraction (LVEF) between ≥20% and ≤40%.
The device is implanted in the catheterization laboratory using a minimally invasive procedure that does not require open-heart surgery. Following implantation, patients receive C-MIC Therapy for a duration of six months. The therapy is designed to improve left ventricular performance, as well as functional capacity and patient well-being, including 6-minute walk distance, quality of life, and New York Heart Association (NYHA) functional class.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Stratum 1: Ischemic Etiology | Other | Device: Subcutaneous cardiac microcurrent treatmentStratum 1a: Active → Inactive Stratum 1b: Inactive → Active |
| Stratum 2: Non-Ischemic Etiology | Other | Device: Subcutaneous cardiac microcurrent treatmentStratum 2a: Active → Inactive Stratum 2b: Inactive → Active |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Only for Stratum 1: Patients with HFrEF with non-ischemic disease etiology1
- Only for Stratum 2: Patients with HFrEF with ischemic disease etiology. All Participants
Key exclusion criteria (29 listed)
- Patients who are not likely to experience improvement of their chronic heart failure by the microcurrent therapy, because the causes of the disease cannot be influenced even if the patients fulfill the indication for use of the device or if the therapy with the C MIC System is not possible or might be associated with unknown risks:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Subcutaneous cardiac microcurrent treatmentThe C-MIC System is implanted subcutaneously using a minimally invasive, non-open-heart procedure performed in a catheterization laboratory. Following randomization, C-MIC Therapy is either inactive or active from Day 1 through Day 180 and active or inactive, respectively, from Day 180 through Day 360. | Device | Stratum 1: Ischemic Etiology, Stratum 2: Non-Ischemic Etiology |
Primary outcome
Change From Baseline in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at Month 6
Time frame: From baseline to 6 months
The Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) assesses heart failure symptoms and physical limitations. Scores range from 0 to 100, with higher scores indicating better health status. Change from baseline is calculated as the Month 6 score minus the baseline score; a positive change indicates improvement.
Change From Baseline in 6-Minute Walk Distance at Month 6
Time frame: From baseline to 6 months
The 6-Minute Walk Test measures functional exercise capacity as the distance, in meters, that a participant can walk in 6 minutes. Change from baseline is calculated as the Month 6 distance minus the baseline distance; a positive change indicates improvement.
Ordinal Shift From Baseline in New York Heart Association Functional Class at Month 6
Time frame: From baseline to 6 months
New York Heart Association (NYHA) Functional Class is a clinician-assessed, 4-category ordinal classification of heart failure severity: Class I indicates no limitation of physical activity, Class II indicates slight limitation, Class III indicates marked limitation, and Class IV indicates symptoms at rest. A shift to a lower class indicates improvement, and a shift to a higher class indicates worsening.
Patient Global Assessment of Change Score at Month 6
Time frame: 6 months
The Patient Global Assessment of Change is a participant-reported assessment of overall change in health status relative to baseline. It is measured on a 7-point ordinal scale ranging from 1 ("markedly worse") to 7 ("markedly improved"), with 4 indicating "no change." Higher scores indicate a more favorable assessment.
Percentage of Participants Who Are Echocardiographic Responders at Month 6
Time frame: From baseline to 6 months
An echocardiographic responder is a participant who meets at least 1 of the following criteria at Month 6 compared with baseline: * Increase in left ventricular ejection fraction (LVEF) of at least 5 percentage points * Improvement in global longitudinal strain (GLS) of at least 2 percentage points, defined as an increase in the absolute magnitude of GLS * Relative reduction in left ventricular end-diastolic volume index (LVEDVi) of at least 10% * Relative reduction in left ventricular end-systolic volume index (LVESVi) of at least 10% Each participant will be counted once as a responder if at least 1 criterion is met. The outcome will be reported as the percentage of participants classified as echocardiographic responders.
Change From Baseline in N-Terminal Pro-B-Type Natriuretic Peptide Concentration at Month 6
Time frame: From baseline to 6 months
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a blood biomarker of heart failure severity and is measured in picograms per milliliter (pg/mL). Change from baseline is calculated as the Month 6 concentration minus the baseline concentration; a negative change indicates a reduction in NT-proBNP.
1 secondary outcome
Change in Left Ventricular Ejection Fraction From Month 6 to Month 12
Time frame: From 6 monts to 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Aug 2026.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Chronic Heart Failure
Recruiting
Laser Acupuncture for Fatigue in Hemodialysis Patients
ESRD (End Stage Renal Disease), Dialysis
RecruitingPhase 3
Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
Heart Failure
RecruitingObservational study
Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)
Kidney Disease, Peritoneal Dialysis (PD)
Active, not recruitingObservational study
Expanded Studies on the SCAPIS Stockholm Reexamination Cohort
Coronary Artery Disease, Arterial Stiffness, Blood Pressure
Not yet recruiting
Exercise, Mediterranean Diet and Inflammation in Heart Failure
Heart Failure, Heart Failure Preserved Ejection Fraction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Subcutaneous cardiac microcurrent treatment in people with Chronic Heart Failure and Left Ventricular (LV) Systolic Dysfunction, run by Berlin Heals GmbH.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 31 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Faouzi Kallel (+1 5106733971, kallel@berlinheals.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at Month 6 (time frame: From baseline to 6 months). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2026.